Stemgent, a REPROCELL Group Company Announces a New High Performance Self-replicative RNA Reprogramming Kit
30 June 2015
Read REPROCELL Group company Stemgent inc.'s announcement of a New High Performance Self-replicative RNA Reprogramming Kit: Stemgent StemRNA™-SR
REPROCELL Concludes the License Agreement with Keio University for the Exclusive Sale of Disease (Hypertrophic Cardiomyopathy) Type Myocardial Cells Derived from iPS Cells
04 June 2015
Read about REPROCELLS exclusive distribution and licensing agreement with Keio University regarding myocardial cells originating from disease type iPS Cells
REPROCELL Acquires the iPS Cell Business Unit of Stemgent, Inc. (USA)
09 September 2014
REPROCELL announced that it will acquire the iPS Cell Business Unit of Stemgent, Inc. allowing REPROCELL to expand the product lineup of its iPSC Business